Expertise in
28
conditions

Dr. Basem William

Hematology
Opg. Blood And Marrow Transplant Clinic
500 Thomas Ln Ste 3A, 
Columbus, OH 
Expertise in
28
conditions
Opg. Blood And Marrow Transplant Clinic
500 Thomas Ln Ste 3A, 
Columbus, OH 

Overview

Basem William is a Hematologist practicing medicine in Columbus, Ohio.

Dr. William is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 15 clinical trials.

Specialties

Hematology

Licenses

Hospitalist in ME

Hospital Affiliations

Grant Medical Center
Marion General Hospital
Riverside Methodist Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Opg. Blood and Marrow Transplant Clinic
500 Thomas Ln Ste 3A, Columbus, OH 43214

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
Enrollment Status: Completed
Publish Date: July 25, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab Vedotin, Lenalidomide
Study Phase: Phase 2
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: May 14, 2025
Intervention Type: Procedure, Drug
Study Drugs: Carmustine, Cytarabine, Etoposide, Melphalan, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Unknown
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 1/Phase 2
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 1
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Withdrawn
Publish Date: December 09, 2021
Intervention Type: Drug
Study Drug: Avatrombopag
Study Phase: Phase 2
View 9 Less Clinical Trials

81 Total Publications

Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.
Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.
Journal: Transplantation and cellular therapy
Published: January 28, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Kami Maddocks
Hematology
Expertise in
22
conditions
Dr. Kami Maddocks
Hematology
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (1.9 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances

Kami Maddocks is a Hematologist practicing medicine in Columbus, Ohio. Dr. Maddocks is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
28
conditions
Dr. Spero Cataland
Hematology
Expertise in
28
conditions
Dr. Spero Cataland
Hematology
Referral may be required

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
 (5.3 miles away)
614-293-9441
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Spero Cataland is a Hematologist practicing medicine in Columbus, Ohio. Dr. Cataland is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, and Splenectomy.

Expertise in
12
conditions
Dr. Jennifer Woyach
Hematology
Expertise in
12
conditions
Dr. Jennifer Woyach
Hematology
Referral may be required

Select Specialty Hosp-Columbus

410 W 10th Ave, 
Columbus, OH 
 (2.7 miles away)
614-293-7677
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jennifer Woyach is a Hematologist practicing medicine in Columbus, Ohio. Dr. Woyach is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Basem William

How do I make an appointment with Dr. Basem William?

You can book an appointment with Dr. Basem William by calling their office at 614-566-2500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Basem William a top-rated expert for Cutaneous T-Cell Lymphoma (CTCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Basem William is classified as an Elite expert for Cutaneous T-Cell Lymphoma (CTCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Basem William specialize in?

While Dr. Basem William is a Hematology, they have specific expertise in Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Mycosis Fungoides. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Basem William participate in research or clinical trials?

Yes. Dr. Basem William has published 81 articles and abstracts on conditions like Cutaneous T-Cell Lymphoma (CTCL). You can view a list of Dr. Basem William's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Basem William accept my insurance?

Dr. Basem William accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-566-2500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. William's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 15 Advanced Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile